Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Kalaris Therapeutics, Inc. Common Stock (KLRS)
Kalaris Therapeutics, Inc. Common Stock
XNAS:KLRS
10.99
5.47%

Ask
$11.24 - 315.00
Bid
$10.99 - 250.00
Low
$9.98
High
$11.88
Open
$10.7
Prev Close
$10.42
52W High
12.9
52W Low
2.14
Volume
477255
Avg Vol (3m)
198005.9
Float
5036762.05
Chart
TendieTensor AI Analysis

Company
Asset Type: Common Stock
SIC Code: 2836
Sector: Health Technology
Industry: Biotechnology
Date Listed: 03/19/2025
Primary Exchange: XNAS

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Phone: 650-249-2727
Address: 628 Middlefield Road
City: Palo Alto
State: CA
Postal Code: 94301
TendieTensor AI Analyst Recommendation:
Fundamentals
P/E (TTM)
-1.410000
P/B (TTM)
4.654940
Round Lot
100
Composit FIGI
BBG00P80SH34
Share Class FIGI
BBG00P80SH43
Share Class Shares Outstanding
18.70M
Weighted Shares Outstanding
18.70M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own KLRS. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.